Clinical ovarian cancer and other gynecologic malignancies最新文献

{"title":"2022-RA-980-ESGO Auranofin as a potential anticancer drug in epithelial ovarian cancer","authors":"Claudia Maccarrone, C. Tucci, G. Orlandi, V. Noferi, L. Nardone, C. Biagiotti, Elisa Wu, Alfonso Altieri, F. Sorbi","doi":"10.1136/ijgc-2022-esgo.611","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.611","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89558361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-966-ESGO Tolerance of intraperitoneal (IP) nivolumab after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with relapse advanced ovarian carcinoma: a phase I study with expansion cohort (ICONIC)","authors":"P. Corbaux, B. You, Naoual Bakrin, O. Glehen, G. Freyer","doi":"10.1136/ijgc-2022-esgo.609","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.609","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81673883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial","authors":"Y. Christinat, Liza Ho, S. Clément, C. Genestie, J. Sehouli, Antonio González Martín, U. Denison, K. Fujiwara, I. Vergote, G. Tognon, S. Hietanen, E. Pujade-Lauraine, I. Ray-Coquard, T. McKee","doi":"10.1136/ijgc-2022-esgo.514","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.514","url":null,"abstract":"2022-RA-567-ESGO Figure 1 Abstracts A238 Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504 on D ecem er 4, 2022 by gest. P rocted by coright. http/ijgc.bm jcom / nt J G ynecol C acer: frst pulished as 10.11ijgc-2022-E S G O .14 on 20 O cber 222. D ow nladed fom Conclusion The proposed test is a viable alternative to the Myriad myChoice HRD test and can easily be implemented in a clinical laboratory for routine practice. The performance of the tests is similar in terms of hazard ratio but the lower failure rate of the Geneva HRD test allows a 10% increase in the number of patients receiving a conclusive laboratory result. 2022-VA-572-ESGO HUDSON POSTERIOR EXENTERATION, WITH THE USE OF ICG FLUORESCENCE TO ASSESS RECTAL ANASTOMOSIS AND URETERAL INTEGRITY Dong Bach Nguyen, Beatriz Navarro Santana, Guillaume Babin, Sara Forte, Mathilde Mairé, Frédéric Guyon. Gynécologie Oncologie, Institut Bergonié, Bordeaux, France 10.1136/ijgc-2022-ESGO.515 Introduction/Background The surgical approach to hysterectomy for ovarian cancer has remained largely unchanged since Hudson described the en-bloc resection of fixed ovarian tumors using a retrograde technique in 1968. When a colorectal resection is required for optimal debulking, anastomotic leak remains a significant concern. While the traditional techniques used to evaluate for anastomotic perfusion lack accuracy, data from a recent systematic review and meta-analysis favours the use of ICG intra-op to reduce the incidence of anastomotic leak and associated need for reintervention. Methodology With the use of surgical footage, this video aims to present the surgical steps to a Hudson procedure with colorectal resection, ending with the use of ICG fluorescence to assess the perfusion of the colorectal anastomosis and ureters. Results The surgical approach can be summarized in the following ten steps: (1) retroperitoneal dissection of the vascular pedicles and ureters, and transection of the IP ligament; (2) dissection of the paravesical and pararectal spaces; (3) lateral and pre-vesical peritonectomy; (4) ureterolysis and transection of the uterine vessels; (5) transection of the vesciouterine and uterosacral ligaments; (6) colpotomy; (7) mesorectal dissection and distal rectal transection; (8) proximal rectosigmoid transection; (9) vaginal vault closure and colorectal anastomosis; (10) assessment of colorectal anastomosis and ureteral vascularization by ICG fluorescence. Conclusion This video presented 10 reproducible steps to perform a Hudson procedure with colorectal resection for ovarian cancer. The use of ICG as an adjunct to assess the vascularization of the colorectal anastomosis appears to reduce the risk of anastomotic leak in colorectal surgery, and may be of interest in gynecologic-oncologic surgery. 2022-RA-576-ESGO EXPRESSION VIII – FIRST STUDY OF INDIVIDUAL PERCEPTION AND LEVEL OF INFORMATION OF PATIENTS WITH LOW GRADE OVARIAN CANCER AND BORDERLINE TUMOR OF THE OVARY IN 321 PATIENTS Laura Naomi Beckma","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89865898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1474-ESGO Traditional systemic treatment options in advance low grade serous ovarian cancer after successful cytoreduction. A systematic review and meta-analysis","authors":"R. M. Macías, P. Rigolet, E. Mikhael, J. Krell, V. Villefranque, F. Lécuru, C. Fotopoulou","doi":"10.1136/ijgc-2022-esgo.725","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.725","url":null,"abstract":"were randomized 2:1 to OLA (n=107) or CT (n=53). Baseline characteristics were similar between both arms. Overall objective response rate (ORR) for OLA and CT were similar (24.3% and 28.3%, respectively). In PSOC, ORR was 35.0% and 65.0% for OLA and CT (p=0.053); in PROC, ORR was 17.9% and 6.1% for OLA and CT (p=0.134). All patients were tested for germline/somatic BRCA1/2 prior to inclusion. 117 FFPE tumor samples at diagnosis were retrieved and tested for HRD with Leuven HRD test. In PSOC Leuven HRD test was a good predictor of PFS benefit with HR0.35 (p=0.035). There was no difference in PFS in PROC based on Leuven HRD status (p=0.274). Myriad myChoiceDX testing on the same samples is ongoing and comparison of HRD test results will be presented at the meeting. Conclusion Leuven HRD test is predictive for OLA efficacy not only in first-line setting but also in recurrent setting in the CLIO trial.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72995233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1029-ESGO Comparison of o-rads and iota adnex model criteria with pathology results in adnexial masses","authors":"Ahmet Arif Filiz, C. Atalay","doi":"10.1136/ijgc-2022-esgo.619","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.619","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80880432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1557-ESGO Mesenteric lymph node involvement in patients undergoing a bowel resection during debulking surgery in advanced ovarian cancer","authors":"F. Galli, G. Candotti, A. Ruffolo, M. Fais, P. de Marzi, M. Peiretti, E. Erdas, S. Angioni, G. Sabetta, L. Bocciolone, M. Candiani","doi":"10.1136/ijgc-2022-esgo.744","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.744","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74815750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-893-ESGO Is ethnicity a risk factor for differential outcomes in mucinous ovarian cancer? experience from a UK gynaecological oncology centre","authors":"Tejumola Olaoye, Kamana Subba, R. Ganesan, Anthony Williams, W. Boyle, J. Bálega, J. Yap, Kavita Singh, S. Sundar","doi":"10.1136/ijgc-2022-esgo.585","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.585","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75052666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-454-ESGO Ovarian metastases from pulmonary cancer – report of two cases","authors":"N. Bacalbaşa, I. Bălescu","doi":"10.1136/ijgc-2022-esgo.508","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.508","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78043608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-792-ESGO Outcomes following Stereotactic Radiotherapy for brain metastasis in ovarian cancer patients","authors":"S. P. Hasson, N. Rosenfelder, Martin Brewer, A. George, L. Welsh, Susana Banerjee","doi":"10.1136/ijgc-2022-esgo.560","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.560","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"320 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76672170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-VA-1553-ESGO Ureteroureterostomy: step by step","authors":"S. Aker","doi":"10.1136/ijgc-2022-esgo.743","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.743","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77133058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}